clinical trial · NCT05566288
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
Achieve Life Sciences·phase1·completed·n = 27
Smoking CessationCytisiniclinePlaceboMoxifloxacin
brief summary
The primary objective of this trial is to assess the effects of cytisinicline at therapeutic and supratherapeutic doses on cardiac repolarization relative to placebo in healthy adult subjects who are smokers.
started
Oct 17, 2022
primary completion
Dec 23, 2022
completion
Dec 23, 2022
last updated
May 18, 2023
official title
A Four Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of Therapeutic and Supratherapeutic Doses of Cytisinicline in Healthy Smokers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol